SVRA · Nasdaq · CIK 0001160308
Savara Inc
Savara Inc’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 25, 2026. Its EDGAR record lists 20 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- Savara Inc
- Ticker
- SVRA
- SEC Central Index Key (CIK)
- 0001160308
- Industry (SIC)
- Pharmaceutical Preparations (code 2834)
- Business address
- AUSTIN, TX
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Non-accelerated filer<br>Smaller reporting company
- Position in SEC ticker list
- #2482 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from Savara Inc’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$118.8M |
| Diluted EPS | -$0.32 | -$0.25 | -$0.33 | -$0.48 | -$0.53 |
| Total assets | $176.6M | $139.8M | $177.6M | $212.9M | $253.4M |
| Cash and equivalents | $34.0M | $52.1M | $26.6M | $15.1M | $33.2M |
XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Mar 13, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 11, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Jun 8, 2026 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results· period Jun 4, 2026 | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Jun 4, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about Savara Inc, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Sep 25, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026 | Document · Index |
| Aug 11, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Aug 11, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Jul 24, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026 | Document · Index |
| Jun 22, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jun 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 22, 2026 | Document · Index |
| Jun 8, 2026 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results· period Jun 4, 2026 | Document · Index |
| May 12, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| Apr 24, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Apr 24, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Jun 4, 2026 | Document · Index |
| Apr 10, 2026 | PRE 14A | PRE 14A· period Jun 4, 2026 | Document · Index |
| Mar 20, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 18, 2026 | Document · Index |
| Mar 13, 2026 | 8-K | Material agreement· period Mar 10, 2026 | Document · Index |
| Mar 13, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Feb 17, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Feb 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 16, 2026 | Document · Index |
| Feb 17, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Feb 13, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Feb 13, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Feb 5, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Jan 27, 2026 | 8-K | Material agreement; New financial obligation· period Jan 26, 2026 | Document · Index |
| Jan 21, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Jan 9, 2026 | 8-K | Regulation FD disclosure· period Jan 9, 2026 | Document · Index |
| Dec 19, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 19, 2025 | Document · Index |
| Dec 18, 2025 | 144 | Notice of proposed sale of securities | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 11, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025 | Document · Index |
| Dec 4, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 4, 2025 | Document · Index |
| Dec 4, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 2, 2025 | Document · Index |
| Nov 17, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Nov 14, 2025 | Document · Index |
Insider filing activity
20 Form 4 filings appear in Savara Inc’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Pharmaceutical Preparations
- LLY ELI LILLY & Co
- JNJ JOHNSON & JOHNSON
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVS NOVARTIS AG
- AZN ASTRAZENECA PLC
- ABT ABBOTT LABORATORIES
- NVO NOVO NORDISK A S
All 194 companies in Pharmaceutical Preparations· Companies headquartered in Texas
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001160308 and XBRL company facts. Savara Inc on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement